Regeneron Pharmaceuticals, Inc. - 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for the period ended September 30, 1998. Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel therapeutics, primarily protein growth factors and small molecule drugs. The company operates through independent research programs and strategic collaborations with major pharmaceutical entities, including The Procter & Gamble Company, Merck & Co., Inc., Amgen Inc., and Sumitomo Pharmaceuticals Co., Ltd.
Key Financial Metrics
| Metric (in thousands) | Q3 1998 | Q3 1997 | 9 Months 1998 | 9 Months 1997 |
|---|---|---|---|---|
| Total Revenues | $12,566 | $8,873 | $36,011 | $21,703 |
| Net Loss | ($1,395) | ($1,907) | ($3,084) | ($12,106) |
| Net Loss Per Share | ($0.04) | ($0.06) | ($0.10) | ($0.43) |
| Cash & Cash Equivalents | $22,594 | $28,921 | $22,594 | $34,475 |
| Total Marketable Securities | $97,784 | $99,120 | $97,784 | $99,120 |
| Total Liquidity (Cash + Securities) | $120,378 | $128,041 | $120,378 | $133,595 |
| Debt (Current + Long Term) | $3,490 | $3,525 | $3,490 | $3,525 |
Note: Debt consists of capital lease obligations and notes payable. Total liquidity includes current and non-current marketable securities.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 42% in Q3 1998 compared to Q3 1997, and 66% for the nine-month period. This was driven by higher contract research revenue from the Procter & Gamble (P&G) agreement and a $5.0 million research progress payment from Sumitomo Pharmaceuticals (net of withholding tax).
- Expense Increases: Operating expenses rose to $14.0 million in Q3 1998 from $10.8 million in Q3 1997. Research and development (R&D) expenses increased significantly due to additional employees and expanded preclinical/clinical activities.
- Improved Profitability: While the company remains unprofitable, the net loss narrowed significantly. The nine-month net loss decreased from $12.1 million in 1997 to $3.1 million in 1998, largely due to increased revenue and a reduction in the loss recognized from the Amgen-Regeneron Partners joint venture.
- Cash Flow: Net cash used in operating activities was $4.5 million for the nine months ended September 30, 1998, compared to $9.2 million in the prior year period. Investing activities consumed $0.7 million, primarily due to net purchases of marketable securities and capital expenditures.
Outlook, Risks, and Management Commentary
- Product Pipeline: The company is advancing AXOKINE for obesity and retinal diseases, with plans to file an Investigational New Drug (IND) application with the FDA in early 1999. Clinical trials for BDNF (for ALS) and NT-3 (for constipating conditions) are ongoing through the Amgen-Regeneron partnership.
- Liquidity Position: As of September 30, 1998, the company held approximately $120.4 million in cash and marketable securities. Management believes these resources are sufficient to meet operating needs for at least several years.
- Collaboration Funding: The company expects to receive up to $100 million or more from P&G through mid-2002 in the form of research funding, milestones, and equity purchases. The P&G agreement covers obesity research, while the Merck agreement covers contract manufacturing.
- Risks: Significant risks include the failure of clinical trials to demonstrate safety or efficacy, delays in regulatory approvals, and the potential termination of key collaboration agreements. The company has no established banking arrangements for short-term financing and relies on equity issuances and collaboration revenue.
- Year 2000 Issues: The company is evaluating Year 2000 compliance for its systems and equipment. While no material issues have been identified in computer systems to date, the analysis of embedded systems in laboratory equipment is incomplete, and costs may increase.
Investor Verification Checklist
- Verify the status and timeline of the planned IND filing for AXOKINE in early 1999.
- Monitor the progress of Phase II clinical trials for BDNF in ALS and NT-3 in enteric neuropathies.
- Review the terms of the P&G collaboration to understand the timing of future milestone payments and equity purchases.
- Assess the company's burn rate relative to its $120.4 million cash position to confirm the "several years" runway estimate.
- Track the resolution of patent interference proceedings regarding CNTF and AXOKINE, specifically the covenant not to sue with Amgen.